These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37779856)

  • 1. Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients.
    Egli-Spichtig D; Hamid AK; Arroyo EMP; Ketteler M; Wiecek A; Rosenkranz AR; Pasch A; Lorenz H; Hellmann B; Karus M; Ammer R; Rubio-Aliaga I; Wagner CA
    Clin Kidney J; 2023 Oct; 16(10):1622-1633. PubMed ID: 37779856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphate control in reducing FGF23 levels in hemodialysis patients.
    Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
    PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism.
    Fořtová M; Hanousková L; Valkus M; Čepová J; Průša R; Kotaška K
    Endocr Connect; 2022 Jan; 11(1):. PubMed ID: 34860179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.
    Yamashita K; Mizuiri S; Nishizawa Y; Kenichiro S; Doi S; Masaki T
    Nephrology (Carlton); 2017 Dec; 22(12):947-953. PubMed ID: 27558654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations.
    Bosman A; Ratsma DM; van der Eerden BC; Zillikens MC
    JBMR Plus; 2023 Oct; 7(10):e10790. PubMed ID: 37808399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.
    Sharma S; Katz R; Ginsberg C; Bullen A; Vallon V; Thomson S; Moe OW; Hoofnagle AN; de Leeuw PW; Kroon AA; Houben AJHM; Ix JH
    J Bone Miner Res; 2022 Jun; 37(6):1170-1178. PubMed ID: 35373859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?
    Bożentowicz-Wikarek M; Kocełak P; Owczarek A; Olszanecka-Glinianowicz M; Mossakowska M; Skalska A; Więcek A; Chudek J
    Clin Biochem; 2015 Apr; 48(6):431-6. PubMed ID: 25583093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High intact fibroblast growth factor 23 levels associated with low hemoglobin levels in patients on chronic hemodialysis.
    Fang YW; Wang JT; Lin TY; Lee CJ; Jang TN; Tsai MH; Liou HH
    Front Med (Lausanne); 2023; 10():1098871. PubMed ID: 37081846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23.
    Hu MC; Reneau JA; Shi M; Takahashi M; Chen G; Mohammadi M; Moe OW
    Am J Physiol Renal Physiol; 2024 Apr; 326(4):F584-F599. PubMed ID: 38299214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly.
    Chudek J; Kocełak P; Owczarek A; Bożentowicz-Wikarek M; Mossakowska M; Olszanecka-Glinianowicz M; Wiecek A
    Nephrol Dial Transplant; 2014 Sep; 29(9):1757-63. PubMed ID: 24729016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-Analysis of the Association between Fibroblast Growth Factor 23 and Mortality and Cardiovascular Events in Hemodialysis Patients.
    Gao S; Xu J; Zhang S; Jin J
    Blood Purif; 2019; 47 Suppl 1(Suppl 1):24-30. PubMed ID: 30699419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-terminal and intact FGF23 in kidney transplant recipients and their associations with overall graft survival.
    Chu C; Elitok S; Zeng S; Xiong Y; Hocher CF; Hasan AA; Krämer BK; Hocher B
    BMC Nephrol; 2021 Apr; 22(1):125. PubMed ID: 33832449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological variability of plasma intact and C-terminal FGF23 measurements.
    Smith ER; Cai MM; McMahon LP; Holt SG
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3357-65. PubMed ID: 22689697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients.
    Hanudel MR; Wesseling-Perry K; Gales B; Ramos G; Campbell V; Ethridge K; Scotti M; Elashoff DA; Alejos J; Reemtsen B; Salusky IB
    Pediatr Nephrol; 2016 Apr; 31(4):661-9. PubMed ID: 26525200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
    Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial.
    Ketteler M; Wiecek A; Rosenkranz AR; Pasch A; Rekowski J; Hellmann B; Karus M; Ammer R
    Kidney Int Rep; 2021 Mar; 6(3):594-604. PubMed ID: 33732974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
    Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
    BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months.
    Enlund-Cerullo M; Hauta-Alus H; Valkama S; Rosendahl J; Andersson S; Mäkitie O; Holmlund-Suila E
    Bone; 2020 Dec; 141():115629. PubMed ID: 32919110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.